

Larsen, J.E., Lin, P., Raaschous-Nielsen, O., Povey, A.C., Reszka, E., Risch, A., Schneider, J., Schwartz, A.G., Sorensen, M., To-Figueras, J., Tokudome, S., Pu, Y., Yang, P., Wenzlaff, A.S., Wikman, H., Taioli, E.					
Ngoan, L.T., Thu, N.T., Lua, N.T., Hang, L.T., Bich, N.N., Hieu, N.V., Quvet, H.V., Tai, L.T., Van, D.D., Khan, N.C., Mai, L.B., Tokudome, S., Yoshimura, T.	Cooking temperature, heat-generated carcinogens, and the risk of stomach cancer and colorectal cancers.	Asian Pacific J. Cancer Prev.	10	83-86	2009

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Miura, S., Kai, Y., Kamei, Y., Bruce, C.R., Kubota, N., Febbraio, M.A., Kadowaki, T., Ezaki, O.	{alpha}2-AMPK activity is not essential for an increase in fatty acid oxidation during low-intensity exercise.	Am. J. Physiol. Endocrinol. Metab.	296	E47-E55	2009
Watanabe, T., Kubota, N., Ohsugi, M., Kubota, T., Takamoto, I., Iwabu, M., Awazawa, M., Katsuyama, H., Hasegawa, C., Tokuyama, K., Moroi, M., Sugi, K., Yamachi, T., Noda, T., Nagai, R., Terauchi, Y., Tobe, K., Ueki, K., Kadowaki, T.	Rimonabant ameliorates insulin resistance via both adiponectin-dependent and adiponectin-independent pathways.	J. Biol. Chem.	284	1803-1812	2009
Nakamura, A., Terauchi, Y., Ohyama, S., Kubota, J., Shimazaki, H., Nambu, T., Takamoto, I.,	Impact of small molecule glucokinase activator on glucose metabolism and beta cell mass.	Endocrinology	150	1147-1154	2009

Kubota, N., Eiki, J., Yoshioka, N., Kadowaki, T., Koike, T.					
Kurabe, N., Arai, S., Nishijima, A., Kubota, N., Suizu, F., Mori, M., Kurokawa, J., Miyazaki, M. K., Ide, T., Murakami, K., Miyake, K., Ueki, K., Koga, H., Yatomi, Y., Tashiro, F., Noguchi, M., Kadowaki, T., Miyazaki, T.	The death effector domain-containing DEDD supports S6K1 activity via preventing Cdk1-dependent inhibitory phosphorylation.	J. Biol. Chem.	284	5050-5055	2009
Aoki, K., Matsui, J., Kubota, N., Nakajima, H., Iwamoto, K., Takamoto, I., Tsuji, Y., Ohno, A., Mori, S., Tokuyama, K., Murakami, K., Asano, T., Aizawa, S., Tobe, K., Kadowaki, T., Terauchi, Y.	The role of the liver in glucose homeostasis in PI 3-kinase p85{alpha}-deficient mice.	Am. J. Physiol. Endocrinol. Metab.	296	E842-E853	2009
Freude, S., Hettich, M. M., Schumann, C., Stöhr, O., Koch, L., Köhler, C., Udelhoven, M., Leiser, U., Müller, M., Kubota, N., Kadowaki, T., Krone, W., Schröder, H., Brüning, J. C., Schubert, M.	Neuronal IGF-1 resistance reduces A{beta} accumulation and protects against premature death in a model of Alzheimer's disease.	FASEB J.	10	3315-33124	2009
Kurita, H., Yoshioka, W., Nishimura, N., Kubota, N., Kadowaki, T., Tohyama, C.	Aryl hydrocarbon receptor-mediated effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on glucose-stimulated insulin secretion in mice.	J. Appl. Toxicol.	29	689-694	2009
Asano, T., Watanabe, K., Kubota, N., Gunji, T., Omata, M., Kadowaki, T.,	Adiponectin knockout mice on high fat diet develop fibrosing steatohepatitis.	J. Gastroenterol. Hepatol.	10	1669-1676	2009

Ohnishi, S.					
-------------	--	--	--	--	--

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Takahashi, S., Takeshita, K., Seeni, A., Sugiura, S., Tang, M., Sato, S., Kuriyama, H., Nakadate, M., Abe, K., Maeno, Y., Nagao, M., Shirai, T.	Suppression of prostate cancer in a transgenic rat model via gamma-tocopherol activation of caspase signaling.	Prostate	69	664-651	2009
Tang, M., Asamoto, M., Ogawa, K., Naiki-Ito, A., Sato, S., Takahashi, S., Shirai, T.	Induction of apoptosis in the LNCaP human prostate carcinoma cell line and prostate adenocarcinomas of SV40T antigen transgenic rats by the Bowman-Birk inhibitor.	Pathol. Int.	59	790-796	2009
Sato, S., Takahashi, S., Asamoto, M., Naiki, T., Naiki-Ito, A., Asai, K., Shirai, T.	Tranilast suppresses prostate cancer growth and osteoclast differentiation <i>in vivo</i> and <i>in vitro</i> .	Prostate	70	229-238	2010

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Uemura, H., Hoshino, K., Sasaki, T., Miyoshi, Y., Ishiguro, H., Inayama, Y., Kubota, Y.	Usefulness of the 2005 International Society of Urological Pathology Gleason Grading System in Prostate Biopsy and Radical Prostatectomy Specimens.	BJU Int.	103	1190-1194	2009
Ishiguro, H., Akimoto, K., Nagashima, Y., Kojima, Y., Sasaki, T., Ishiguro-Imagawa, Y., Nakaigawa, N., Ohno, S., Kubota, Y., Uemura, H.	Atypical protein kinase C 1/i promotes growth of prostate cancer cells in an autocrine manner through transcriptional activation of interleukin-6.	Proc. Natl. Acad. Sci. U S A.	106	16369-167 4	2009

Minamimoto, R., Tateishi, U., Uemura, H., Yamanaka, S., Kubota, Y., Inoue, T.	Avid F-18 FDG uptake in prostatic sarcoma.	Clin. Nucl. Med.	34	388-389	2009
--	---	---------------------	----	---------	------

雑誌

発表者氏名	論文タイトル名	発表誌名	巻 号	ページ	出版年
Imaoka, T., Nishimura, M., Iizuka, D., Daino, K., Takabatake, T., Okamoto, M., Kakinuma, S., Shimada, Y.	Radiation-induced mammary carcinogenesis in rodent models: what's different from chemical carcinogenesis?	J. Radiat. Res.	50	281-293	2009
Miyoshi-Imamura, T., Kakinuma, S., Kaminishi, M., Okamoto, M., Takabatake, T., Nishimura, Y., Imaoka, T., Nishimura, M., Murakami-Murofushi, K., Shimada, Y.	Unique characteristics of radiation-induced apoptosis in the postnatally developing small intestine and colon.	Radiat. Res.	173	310-318	2010
Yamaguchi, Y., Takabatake, T., Kakinuma, S., Amasaki, Y., Nishimura, M., Imaoka, T., Yamauchi, K., Shang, Y., Miyoshi-Imamura, T., Nogawa, H., Kobayashi, Y., Shimada, Y.	Complicated biallelic inactivation of <i>Pten</i> in radiation-induced mouse thymic lymphomas.	Mutat. Res.			2010 (in press)
Hamada, N., Imaoka, T., Masunaga, S., Ogata, T., Okayasu, R., Takahashi, A., Kato, T., Kobayashi, Y., Ohnishi, T., Ono, K., Shimada, Y., Teshima, T.	Recent advances in the biology of heavy-ion cancer therapy.	J. Radiat. Res.			2010 (in press)

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Matsuno, R. K., Anderson, W. F., <u>Yamamoto, S.</u> , Tsukuma, H., Pfeiffer, R. M., Kobayashi, K., Devesa, S. S., Levine, P. H.	Early- and late-onset breast cancer types among women in the United States and Japan.	Cancer Epidemiol. Biomarkers Prev.	16	1437-1442	2007
Iwasaki, M., Inoue, M., Otani, T., Sasazuki, S., Kurahashi, N., Miura, T., <u>Yamamoto, S.</u> , Tsugane, S.	Plasma isoflavone level and subsequent risk of breast cancer among Japanese women: a nested case-control study from the Japan public health center-based prospective study group.	J. Clin. Oncol.	26	1677-1683	2008
Iwasaki, M., Hamada, G. S., Nishimoto, I. N., Netto, M. M., Motola, J. Jr., Laginha, F. M., Kasuga, Y., Yokoyama, S., Onuma, H., Nishimura, H., Kusama, R., Kobayashi, M., Ishihara, J., <u>Yamamoto, S.</u> , Hanaoka, T., Tsugane, S.	Isoflavone, polymorphisms in estrogen receptor genes and breast cancer risk in case-control studies in Japanese, Japanese Brazilians and non-Japanese Brazilians.	Cancer Sci.	100	927-933	2009
Iwasaki, M., Hamada, G. S., Nishimoto, I. N., Netto, M. M., Motola, J. Jr., Laginha, F. M., Kasuga, Y., Yokoyama, S., Onuma, H., Nishimura, H., Kusama, R., Kobayashi, M.,	Dietary isoflavone intake and breast cancer risk in case-control studies in Japanese, Japanese Brazilians, and non-Japanese Brazilians.	Breast Cancer Res. Treat.	116	401-411	2009

Ishihara, J., Yamamoto, S., Hanaoka, T., Tsugane, S. Sakai, T., Matsuura, N.					
--	--	--	--	--	--

#### IV. 研究成果の刊行物・別冊

## Overexpression of low-density lipoprotein receptor and lipid accumulation in intestinal polyps in Min mice

Michihiro Mutoh\*, Masami Komiya, Naoya Teraoka, Toshiya Ueno, Mami Takahashi, Tsukasa Kitahashi, Takashi Sugimura and Keiji Wakabayashi

Cancer Prevention Basic Research Project, National Cancer Center Research Institute, Chuo-ku, Tokyo, Japan

*Apc*-deficient Min mice feature low expression of lipoprotein lipase (LPL), high concentration of serum triglyceride (TG), fatty change of the liver and large numbers of intestinal polyps. We have reported that induction of LPL expression reduces serum lipid, especially TG, improves fatty change of the liver and inhibits intestinal polyp formation in the mice. In this study, fatty change/lipid accumulation in intestinal mucosa and polyps in Min mice were analyzed by Oil-red O staining and electron microscopy. A number of large lipid droplets were found in the epithelia of the upper part of polyps. On the other hand, small lipid droplets were only slightly observed at the tip of the villi in non-tumor parts of the small intestine of Min mice and in the villi of wild-type mice. Moreover, low-density lipoprotein receptor (LDLR) was overexpressed in the area where lipid droplets were observed. The expression levels of LDLR mRNA in the intestinal polyps of Min mice were ~3 times higher compared to those in the non-tumor parts. Remarkable expression of cyclooxygenase-2 was mainly distributed in stromal cells and some in epithelial cells. It is speculated that lipid accumulation in the intestinal polyps may play an important role in intestinal polyp formation in *Apc*-deficient mice. © 2009 UICC

**Key words:** *Apc*-deficient mice; low-density lipoprotein receptor; lipid accumulation; triglyceride; intestinal polyp

The incidence and mortality of colon cancer, one of the most common cancers, is increasing in developed countries. High fat diet consumption, obesity and hyperlipidemia, especially hypertriglyceridemia, are linked to the increased risk of colorectal tumor.<sup>1–5</sup> Recently, we reported an age-dependent hyperlipidemic state in *adenomatous polyposis coli* (*Apc*)-deficient Min and *Apc*<sup>1309</sup> mice, animal models of familial adenomatous polyposis (FAP).<sup>6,7</sup> *Apc*-deficient mice develop large numbers of intestinal polyps due to a truncation mutation in the *Apc* gene leading to an activation of Wnt signaling to promote cell growth.

Although the direct link between *Apc*-deficiency and hyperlipidemia has yet to be clarified, it is notable that serum triglyceride (TG) levels in *Apc*-deficient mice are almost 10-fold more than those observed in wild-type littermates (C57BL/6J).<sup>6</sup> TG is rich in lipoproteins such as chylomicrons (CM), very low-density lipoprotein (VLDL) and low-density lipoprotein (LDL), and is hydrolyzed by lipoprotein lipase (LPL) to free fatty acids and monoacylglycerol. High populations of lipoproteins are VLDL (~50%) and LDL (~25%), TG-rich lipoproteins, in Min mice, while high-density lipoprotein (~80%) in wild-type mice.<sup>6–8</sup> Physiologically, decrease or deficiency of LPL is associated with hyperlipidemic state<sup>9,10</sup> and *Apc*-deficient mice showed decreased expression levels for LPL mRNA in the liver and small intestine, supposed to be the reason for hypertriglyceridemic status. In addition to high concentration of the lipid in the serum, steatosis of the liver is observed in Min mice, which was confirmed by staining frozen sections with Oil-red O.<sup>6</sup> Moreover, we have demonstrated that induction of LPL mRNA by peroxisome proliferator-activated receptor (PPAR)- $\alpha$  and - $\gamma$  agonists and a selective LPL-inducing agent, NO-1886, which lacks potential for activating the PPAR pathways, suppressed the hyperlipidemic status, steatosis of the liver and intestinal polyp formation.<sup>6–8</sup> However, fatty changes in the intestinal mucosa including lipid accumulation in Min mice intestinal polyp have remained to be elucidated.

Regarding intestinal digestion of dietary fat, fat in the intestinal content changes to micellar solubilization form due to the action

of amphipathic bile salts and pancreatic lipase.<sup>11</sup> Further hydrolysis by pancreatic lipase to form smaller micelles (30–100 Å) helps lipid absorption through small intestinal epithelia, and this lipid absorption would occur through passive diffusion and through endocytosis-dependent pathways using receptors. The LDL receptor (LDLR) has been reported to regulate the majority of essential fatty acid uptake as well as cholesterol uptake into cells.<sup>12</sup> Moreover, it has been reported that LDL plays an important role in cell growth of human colon cancer cells.<sup>13</sup> After penetration of micelles, through the brush border of the small intestine, CM are synthesized in the epithelial cells. Then, CM is released from small intestinal epithelial cells to circulate through the lymphatic system and finally, taken up by the liver.

It is possible that the efficiency of intestinal lipid absorption is increased in the *Apc*-deficient mice and induces lipid accumulation in the intestinal mucosa. In this study, we examined the lipid accumulation in intestinal polyps developed in Min mice by Oil-red O staining and electron microscopy examination and found a number of large lipid droplets accumulated in the epithelium of polyps. Moreover, immunohistochemical staining revealed that LDLR and cyclooxygenase-2 (COX-2) were overexpressed in the epithelia where lipid droplets were observed. The possible mechanisms inducing lipid accumulation in intestinal polyps and the effects of lipid accumulation on the development of polyps in *Apc*-deficient mice are also discussed.

### Material and methods

#### Animals

Male C57BL/6-*Apc*<sup>Min/+</sup> mice (Min mice) were purchased from The Jackson Laboratory at 6 weeks of age and genotyped as previously reported.<sup>14</sup> Heterozygotes of the Min strain and wild-type (C57BL/6J) mice were acclimated to laboratory conditions for 1 week. Five mice were housed per plastic cage with sterilized soft-wood chips as bedding in a barrier-sustained animal room at 24°C  $\pm$  2°C and 55% humidity on a 12 hr light/dark cycle.

To investigate the lipid accumulation in intestinal polyps, male Min mice ( $n = 5$ ) and wild-type mice ( $n = 5$ ) at 7 weeks of age were given AIN-76A powdered basal diet (CLEA Japan, Tokyo, Japan) for 8 weeks. Food and water were available *ad libitum*. The animals were observed daily for clinical signs and mortality. Body weights and food consumption were measured weekly. The experimental protocol was in accordance with the guidelines for Animal Experiments in the National Cancer Center and was approved by the Institutional Ethics Review Committee for Animal Experimentation.


**Abbreviations:** CM, chylomicrons; COX-2, cyclooxygenase-2; FAP, familial adenomatous polyposis; LDL, low-density lipoprotein; LPL, lipoprotein lipase; PPAR, peroxisome proliferator-activated receptor; TG, triglyceride; VLDL, very low-density lipoprotein.

Grant sponsors: Grants-in-Aid for Cancer Research, for the Third-Term Comprehensive 10-Year Strategy for Cancer Control from the Ministry of Health, Labor, and Welfare of Japan, The Yakult Bio-science Foundation.

\*Correspondence to: Cancer Prevention Basic Research Project, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. Fax: +81-3-3542-9305. E-mail: mimutoh@ncc.go.jp

Received 25 December 2008; Accepted after revision 4 June 2009  
DOI 10.1002/ijc.24667

Published online 19 June 2009 in Wiley InterScience (www.interscience.wiley.com).



**FIGURE 1** – Lipid accumulation observed in epithelial cells of polyp part of Min mice. Frozen sections of intestinal tissues were stained with Oil-red O as described in the text. Lipid droplets were stained in red. Arrows indicate the lipid droplets. Bars represent 200  $\mu\text{m}$ . (a) Small intestinal polyp part of Min mice. (b) Large magnification of lipid droplets shown in yellow square part of (a). (c) Colon polyp part of Min mice. (d) Non-tumorous part of small intestinal tissue of Min mice. Larger magnification of a pointed part was inserted with the square. (e) Non-tumorous part of colon tissue of Min mice. (f) Small intestinal tissue of wild-type mice. Larger magnification of a pointed part was inserted with the square.


#### *Intestinal polyp assessment*

The intestinal tract was removed and separated into the small intestine, cecum and colon. The small intestine was divided into the proximal segment (4 cm in length), and then the middle and distal halves of the remainder. All polyps in the proximal segments were picked up under a stereoscopic microscope and the remaining intestinal mucosa was removed by scraping, and then both stored at  $-80^{\circ}\text{C}$ . The stored samples from proximal seg-

ments were used for further RT-PCR analysis. Other segments ( $n = 5$ ) were opened longitudinally and fixed flat between sheets of filter paper in 10% buffered formalin<sup>6</sup> for further Oil-red O staining and immunohistochemical staining.

#### *Oil-red O staining*

Fat droplets within digestive tissues, such as esophagus, glandular stomach, small intestine and colon, were observed using a



**FIGURE 2** – Transmission electron microscopy of epithelial cells of non-tumorous part and polyp part of the small intestine in Min mice. Bars represent 3  $\mu$ m. (a) Non-tumorous part of the small intestine in Min mice. Magnification  $\times 3,500$ . (b) Small intestinal polyp part of Min mice. Arrows indicates one of the lipid droplets. Magnification  $\times 1,800$ .

modified Oil-red O staining method.<sup>15</sup> In brief, frozen sections were treated with 60% 2-propanol for 1 min, stained with Oil-red solution for 15 min at room temperature. The dye was then removed, and the sections were washed with PBS and 60% 2-propanol each for 2 min. Images of tissues stained with Oil-red O were obtained with an Olympus digital camera.

#### Immunohistochemical staining

The middle and distal segments of the small intestines were fixed, embedded and sectioned as Swiss rolls for further immunohistochemical examination with the avidin-biotin complex immunoperoxidase technique, and polyclonal goat anti-mLDLR antibody (R&D systems, Minneapolis, MN) at 50 $\times$  dilution, polyclonal rabbit anti-p-Akt antibody (Ser 473; Santa Cruz Biotechnology, Santa Cruz, CA) and polyclonal goat anti-COX-2 antibody (C-20; Santa Cruz Biotechnology) at 100 $\times$  dilution. As the secondary antibody, biotinylated anti-goat IgG, and absorbed with rat serum (Vector Laboratories, Burlingame, CA) was employed at 200 $\times$  dilution. Staining was performed using avidin-biotin reagents (Vectastain ABC reagents; Vector Laboratories), 3,3'-diaminobenzidine and hydrogen peroxide, and the sections were counterstained with hematoxylin to facilitate orientation. As a negative control, consecutive sections were immunostained without exposure to the primary antibody.

#### Western blot analysis

Samples from small intestinal polyps and non-tumorous parts of small intestines in Min mice were lysed in 100  $\mu$ l lysis buffer [0.0625 M Tris-HCl (pH 6.8), 20% 2-mercaptoethanol, 10% glyc-

erol, 5% SDS]. Thirty  $\mu$ g of protein were separated in 10% PAGE-SDS gels and transferred onto polyvinylidene difluoride membranes (Millipore, Billerica, MA). Antibodies against the LDLR (R&D systems) and  $\beta$ -actin (Biomedical Technologies, Stoughton, MA) were used at a 1:1,000 dilution. Peroxidase-conjugated secondary antibodies for anti-rabbit IgG were obtained from GE Healthcare, UK. Blots were developed with ECL western blotting detection reagents (GE Healthcare, Buckinghamshire, UK).

#### Electron microscope

For transmission electron microscopy, tissues from middle segments of small intestine were fixed with 2.5% glutaraldehyde for 2 hr at 4 $^{\circ}$ C. Specimens were fixed with 1% osmium tetroxide for an additional 2 hr at 4 $^{\circ}$ C, dehydrated in alcohol and embedded in Epon. Thin sections were stained with uranyl acetate and lead citrate, and photographed using H-7500 transmission electron microscope (Hitachi High-Technologies, Japan).

#### Real-time PCR analysis

Tissue samples including polyp part and non-tumorous part from the proximal segments of mice were rapidly deep-frozen in liquid nitrogen and stored at  $-80^{\circ}$ C. Total RNA was isolated from tissues by using Isogen (Nippon Gene, Tokyo, Japan), treated with DNase (Invitrogen, Carlsbad, CA) and 3  $\mu$ g aliquots in a final volume of 20  $\mu$ l were used for synthesis of cDNA using an Omniscript RT Kit (Qiagen, Hilden, Germany) and an oligo(dT) primer. Real-time PCR was carried out using a DNA Engine Opticon TM 2 (MJ Japan, Tokyo, Japan) with SYBR Green Realtime PCR Master Mix (Toyobo, Osaka, Japan) according to the manufacturer's instructions. Primers for mouse LDLR (5' primer-TCCAATCAATTCAGCTGTGG, 3' primer-GAGCCATCTAGGC AATCTCG) and GAPDH (5' primer-TTGTCTCTCGCGAC TTCA, 3' primer-CACCACCCTGTTGCTGTA) were employed.<sup>16</sup> To assess the specificity of each primer set, amplicons generated from the PCR reaction were analyzed for melting curves and also by electrophoresis in 2% agarose gels.

#### Statistical analysis


The student's *t*-test was used for statistical analyses of the intestinal LDLR mRNA level. Differences were considered to be statistically significant at  $p < 0.05$ .

## Results

#### Accumulation of lipids in intestinal polyps of Min mice

The body weights of Min mice and wild-type mice were almost the same during the study, and the final body weights were 26.3 and 28.7 g, respectively. Average daily food intake of Min mice and wild-type mice did not differ significantly. Consistent to the previous study, Min mice developed almost all polyps in the small intestine, with only a few found in the colon.<sup>6</sup> The average number of intestinal polyps developed in Min mice was  $70.6 \pm 14.8$  (mean  $\pm$  SD). However, none of the wild-type mice developed intestinal polyps.

To determine whether lipid accumulation was present in intestinal polyps and/or non-tumorous part, frozen sections of Swiss-rolled middle and distal parts of the small intestine were stained with Oil Red O solution and were examined. A number of large lipid droplets were found in the epithelium of upper part of polyps in the small intestine (Figs. 1a and 1b). In 2 of 3 colon polyps, a few large lipid droplets were also found in the epithelium of upper part of polyps (Fig. 1c). On the other hand, small lipid droplets were slightly observed at the tip of villi of non-tumorous parts in the middle and distal parts of small intestine of Min mice (Fig. 1d). There were no lipid droplets found in mucosa of non-tumorous part of colon (Fig. 1e). In the middle and distal parts of small intestinal mucosa of wild-type mice, small lipid droplets were slightly observed at the tip of the villi (Fig. 1f). High magnification at the bottom of villi showed small lipid droplets under the epithel-



**FIGURE 3** – LDLR overexpression in intestinal polyps. (a) Immunohistochemical staining of LDLR protein in polyp parts of the small intestine of a Min mouse. Bars represent 200 μm. (b) Large magnification of immunohistochemical staining of LDLR protein shown in yellow square part of (a). (c) Quantitative real-time PCR analysis of LDLR mRNA expression in intestinal mucosa of wild-type mice ( $n = 5$ ), non-tumorous part of intestinal mucosa of Min mice and intestinal polyps of Min mice ( $n = 5$ ). Data are means  $\pm$  SD. Normalized by GAPDH. \* $p < 0.05$  (vs. WT); \*\* $p < 0.01$  (vs. WT or vs. Non-T). WT, small intestinal mucosa in wild-type mice; Non-T, small intestinal mucosa in non-tumorous part; T, tumorous part. (d) Western blot analysis of LDLR protein expression in intestinal mucosa of wild-type mice ( $n = 3$ ), non-tumorous parts of intestinal mucosa of Min mice and intestinal polyps of Min mice ( $n = 3$ ).  $\beta$ -actin was used as loading control.

lial cells, suggesting CM released from epithelial cells to circulate through the lymphatic system. Oil-red O staining was further performed in esophagus and glandular stomach, and revealed that there were no lipid droplets in mucosa of these organs (data not shown).

Examining under an electron microscope, microvilli, mitochondria and nuclei of epithelial cells from non-tumorous part of Min mice appeared intact, and small lipid droplets were observed in the cytoplasm (Fig. 2a). On the other hand, epithelial cells from intestinal polyps were shown to have huge lipid droplets, occupying almost all the cytoplasm with depressed nuclei (Fig. 2b).

#### Overexpression of LDLR in intestinal polyps of Min mice

We investigated the localization and expression levels of LDLR in polyps and non-tumorous part of Min mice. Strong immunohistochemical staining for LDLR was observed in epithelial cells at the surface of small intestinal polyps of Min mice, especially, in the area where lipid droplets were observed (Figs. 3a and 3b). Weak LDLR staining was observed in the non-tumorous part as shown in Figure 3a. These LDLR staining were not observed in the small intestinal villi of wild-type mice, and no artificial staining was detected in controls using the secondary antibody only (data not shown).

Real-time PCR revealed that LDLR mRNA level in intestinal polyps was obviously increased (~4 times) as compared with non-tumorous part of intestine in Min mice (Fig. 3c). LDLR mRNA levels in the Min mice polyps were also almost 10-fold elevated as compared with intestinal mucosa of wild-type mice (Fig. 3c). Moreover, a Western blot analysis was performed for protein expression levels of LDLR in intestinal tumorous parts and non-tumorous parts of normal mucosa, and weak but confidential expression levels of LDLR in intestinal tumor part were detected (Fig. 3d).

#### Localization of COX-2 in intestinal polyps of Min mice

To further explore possible mechanisms whereby an accumulated lipid leads to the epithelial cell proliferation and intestinal tumor promotion, localization of COX-2 in small intestinal polyps of Min mice was investigated. Consistent with previous reports,<sup>17</sup> levels of COX-2 protein were found to be very low in the normal mucosa, while the protein was found to be expressed in large quantities in the polyp stroma near the luminal surface (Fig. 4a). Interestingly, in some part, COX-2 staining was observed in the cytoplasm of epithelial cells (Fig. 4b). As demonstrated in Figure 4c, Akt phosphorylation was observed ubiquitously in the epithelial cells of intestinal polyps.




FIGURE 4 – Immunohistochemical staining of COX-2 protein in intestinal polyps of Min mice. (a) COX-2 expression in stromal cells of the small intestinal polyps. Bars represent 200  $\mu\text{m}$ . (b) COX-2 expression shown in epithelial cells of Min mouse intestinal polyp. Arrows indicate COX-2 staining. Bars represent 50  $\mu\text{m}$ . (c) Phosphorylated Akt expression shown in epithelial and stromal cells of Min mouse intestinal polyp. Bars represent 100  $\mu\text{m}$ .

## Discussion

In this study, lipid droplets were observed in the small intestinal and colorectal polyps of Min mice, occurring at the surface epithelium and coinciding with an overexpression of LDLR found in the same area. COX-2 was also expressed in stromal and epithelial cells. It is therefore speculated that lipid accumulation in the intes-

tinal polyps may play an important role in intestinal polyp development in *Apc*-deficient mice.

To our knowledge, lipid accumulation in the tumor epithelial cells has not yet been reported in experimental colon carcinogenesis models, although that in human colon cancer was reported quite recently.<sup>18</sup> It has been observed that number of lipid droplets increased in human colon adenocarcinoma cells when compared with an adjacent normal cells from the same patient submitted to surgical resection. In this study, many large lipid droplets were found in the epithelium of upper part of polyps, while small lipid droplets were only slightly observed at the tip of the villi in non-tumorous parts of Min mice. Dietary fat moves in intestinal tract, contacting with the tip of the villi. Lipid may be largely absorbed at the tip of the villi. Moreover, accumulation of lipids is localized in the cytoplasm of intestinal epithelial cells, but not in stromal cells, supporting the idea that the origin of accumulated lipids are from the content in digestive tract and not from blood vessels.

From our results, it is speculated that there are 2 possible mechanisms regarding intestinal tumor cell growth. One might be the direct effect of TG or LDL receptor-mediated stimuli on epithelial cells, and the other might be the effect of prostaglandin  $E_2$  ( $PGE_2$ ) produced by COX-2 in stromal cells on epithelial cells. Recent evidence indicates that the members of the LDL receptor gene family could activate the phosphoinositide (PI) 3-kinase-mediated pathway, involving phosphorylation of Akt, through cytoplasmic tail of the receptor containing the consensus tetrapeptide Asn-Pro-Xaa-Tyr (NPxY).<sup>19,20</sup> Activation of Akt plays a critical role in controlling survival and apoptosis.<sup>21-23</sup> It has been reported that TG-rich lipoproteins from type IV hyperlipidemic patients induce phosphorylation of p38 MAPK, CREB and I $\kappa$ B $\alpha$ , and activate DNA binding activity of transcriptional factors, CREB, NF- $\kappa$ B and AP-1 in endothelial cells.<sup>24</sup> In addition, treatment with LDL on smooth muscle cells results in the activation of protein kinase C and MAP kinase as well as the induction of the cell cycle-related genes, *c-fos*, *c-myc* and early growth response gene-1.<sup>25</sup>

We found that LDLR mRNA expression in non-tumorous part of intestinal mucosa in Min mice was higher compared to those of wild-type mice, suggesting the high efficiency of intestinal lipid absorption in Min mice. Certain tumors, such as human colorectal carcinomas,<sup>26</sup> and human lung adenocarcinoma cell lines A549,<sup>27</sup> express huge amount of LDLR. It has been shown that COX-2 is up-regulated in colorectal adenocarcinomas specimens, having overexpressed LDLR mRNA compared with normal mucosa.<sup>28</sup> Our present data also showed that COX-2 was expressed in large quantities in the polyp stroma near the luminal surface where LDLR was up-regulated. Moreover, it has been demonstrated that  $PGE_2$  produced by stromal cells affects on epithelial cells through  $EP_2$  receptor.<sup>29</sup> Taken together, we postulate that the intestinal polyps in the Min mice with high levels of COX-2 expression respond to inappropriate uptake of fatty acids through LDLR. However, further experiments are needed to clarify a functional relationship between LDLR and COX-2.

In conclusion, this study indicated that lipid accumulation and overexpression of LDLR in polyp epithelium may contribute to polyp development. Thus, LDLR is suggested to be a potential target site for chemoprevention of colon cancer. As it is becoming increasingly clear that high fat diet, obesity and hyperlipidemia are important players in carcinogenesis, our observations may lead to a better understanding of the role of lipid accumulation in colon carcinogenesis.

## Acknowledgements

During the performance of this work, Dr. T. Kitahashi was the recipient of a Research Resident fellowship from the Foundation for Promotion of Cancer Research.

## References

1. Le Marchan L, Wilkens LR, Kolonel LN, Hankin JH, Lyu LC. Associations of sedentary lifestyle, obesity, smoking, alcohol use, and diabetes with the risk of colorectal cancer. *Cancer Res* 1997;57:4787-94.
2. Abu-Abid S, Szold A, Klausner J. Obesity and cancer. *J Med* 2002;33:73-86.
3. Yamada K, Araki S, Tamura M, Sakai I, Takahashi Y, Kashihara H, Kono S. Relation of serum total cholesterol, serum triglycerides and fasting plasma glucose to colorectal carcinoma *in situ*. *Int J Epidemiol* 1998;27:794-8.
4. Kaye JA, Meier CR, Walker AM, Jick H. Statin use, hyperlipidaemia, and the risk of breast cancer. *Br J Cancer* 2002;86:1436-9.
5. Otani T, Iwasaki M, Ikeda S, Kozu T, Saito H, Mutoh M, Wakabayashi K, Tsugane S. Serum triglycerides and colorectal adenoma in a case-control study among cancer screening examinees (Japan). *Cancer Causes Control* 2006;17:1245-52.
6. Niho N, Takahashi M, Kitamura T, Shoji Y, Itoh M, Noda T, Sugimura T, Wakabayashi K. Concomitant suppression of hyperlipidemia and intestinal polyp formation in *Apc*-deficient mice by peroxisome proliferator-activated receptor ligands. *Cancer Res* 2003;63:6090-5.
7. Niho N, Takahashi M, Shoji Y, Takeuchi Y, Matsubara S, Sugimura T, Wakabayashi K. Dose-dependent suppression of hyperlipidemia and intestinal polyp formation in Min mice by pioglitazone, a PPAR gamma ligand. *Cancer Sci* 2003;94:960-4.
8. Niho N, Mutoh M, Takahashi M, Tsutsumi K, Sugimura T, Wakabayashi K. Concurrent suppression of hyperlipidemia and intestinal polyp formation by NO-1886, increasing lipoprotein lipase activity in Min mice. *Proc Natl Acad Sci USA* 2005;102:2970-4.
9. Gehrlich S. Common mutations of the lipoprotein lipase gene and their clinical significance. *Curr Atheroscler Rep* 1999;1:70-8.
10. Mead JR, Irvine SA, Ramji DP. Lipoprotein lipase: structure, function, regulation, and role in disease. *J Mol Med* 2002;80:753-69.
11. Jones PJH, Kubow S. Lipids, sterols, and their metabolites. In: Shiels ME, Olson JA, Shike M, Ross AC, eds. *Modern nutrition in health and disease*, 9th edn. Baltimore, MD: Williams & Wilkins, 1999. 67-94.
12. Habenicht AJR, Salbach PD, Janssen-Timmen U. LDL receptor-dependent polyunsaturated fatty acid transport and metabolism. *Eicosanoids* 1992;5:529-31.
13. Lum DF, McQuaid KR, Gilbertson VL, Hughes-Fulford M. Coordinate up-regulation of low-density lipoprotein receptor and cyclooxygenase-2 gene expression in human colorectal cells and in colorectal adenocarcinoma biopsies. *Int J Cancer* 1999;83:162-6.
14. Moser AR, Pitot HC, Dove WF. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. *Science* 1990;247:322-4.
15. Green H, Kehinde O. An established preadipose cell line and its differentiation in culture. II. Factors affecting the adipose conversion. *Cell* 1975;5:19-27.
16. Swertfeger DK, Bu G, Hui DY. Low density lipoprotein receptor-related protein mediates apolipoprotein E inhibition of smooth muscle cell migration. *J Biol Chem* 2002;277:4141-6.
17. Oshima M, Dinichuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, Trzaskos JM, Evans JF, Taketo MM. Suppression of intestinal polyposis in *Apc716* knockout mice by inhibition of cyclooxygenase 2 (COX-2). *Cell* 1996;87:803-9.
18. Accioly MT, Pacheco P, Maya-Monteiro CM, Carrossini N, Robbs BK, Oliveira SS, Kaufmann C, Morgado-Diaz JA, Bozza PT, Viola JP. Lipid bodies are reservoirs of cyclooxygenase-2 and sites of prostaglandin-E<sub>2</sub> synthesis in colon cancer cells. *Cancer Res* 2008;68:1732-40.
19. Stolt PC, Bock HH. Modulation of lipoprotein receptor functions by intracellular adaptor proteins. *Cell Signal* 2006;18:1560-71.
20. Stolt PC, Chen Y, Liu P, Bock HH, Blacklow SC, Herz J. Phosphoinositide binding by the disabled-1 PTB domain is necessary for membrane localization and reelin signal transduction. *J Biol Chem* 2005;280:9671-7.
21. Franke TF, Kaplan DR, Cantley LC. PI3K: downstream AKTion blocks apoptosis. *Cell* 1997;88:435-7.
22. Burgering BM, Coffey PJ. Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. *Nature* 1995;376:599-602.
23. Franke TF, Yang SL, Chan TO, Datta K, Kazlauskas A, Morrison DK, Kaplan DR, Tsichlis PN. The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. *Cell* 1995;81:727-36.
24. Norata GD, Grigore L, Raselli S, Redaelli L, Hamsten A, Maggi F, Eriksson P, Catapano AL. Post-prandial endothelial dysfunction in hypertriglyceridemic subjects: molecular mechanisms and gene expression studies. *Atherosclerosis* 2007;193:321-7.
25. Sachinidis A, Ko Y, Wiczorek A, Weisser B, Locher R, Vetter W, Vetter H. Lipoproteins induce expression of the early growth response gene-1 in vascular smooth muscle cells from rat. *Biochem Biophys Res Commun* 1993;192:794-9.
26. Caruso MG, Notarnicola M, Cavallini A, Guerra V, Misciangna G, Di Leo A. Demonstration of low density lipoprotein receptor in human colonic carcinoma and surrounding mucosa by immunoenzymatic assay. *Ital J Gastroenterol* 1993;25:361-7.
27. Gueddari N, Favre G, Hachem H, Marek E, Le Gaillard F, Soula G. Evidence for up-regulated low density lipoprotein receptor in human lung adenocarcinoma cell line A549. *Biochimie* 1993;75:811-9.
28. Notarnicola M, Altomare DF, Calvani M, Orlando A, Bifulco M, D'Attoma B, Caruso MG. Fatty acid synthase hyperactivation in human colorectal cancer: relationship with tumor side and sex. *Oncology* 2006;71:327-32.
29. Sonoshita M, Takaku K, Sasaki N, Sugimoto Y, Ushikubi F, Narumiya S, Oshima M, Taketo MM. Acceleration of intestinal polyposis through prostaglandin receptor EP<sub>2</sub> in *Apc<sup>Delta 716</sup>* knockout mice. *Nat Med* 2001;7:1048-51.

## Visceral Fat Volume and the Prevalence of Colorectal Adenoma

Taiki Yamaji\*, Motoki Iwasaki, Shizuka Sasazuki, Norie Kurahashi, Michihiro Mutoh, Shuji Yamamoto, Masahiro Suzuki, Noriyuki Moriyama, Keiji Wakabayashi, and Shoichiro Tsugane

\* Correspondence to Dr. Taiki Yamaji, Epidemiology and Prevention Division, Research Center for Cancer Prevention and Screening, National Cancer Center, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan (e-mail: tyamaji@ncc.go.jp).

Initially submitted May 15, 2009; accepted for publication September 3, 2009.

Few epidemiologic investigations of visceral adiposity and colorectal neoplasms have attempted the direct quantification of visceral fat. The authors measured visceral fat volume among middle-aged and elderly Japanese men and women who underwent colonoscopy and positron emission tomography/computed tomography for cancer screening in Tokyo, Japan, between February 2004 and February 2005, and examined the association between visceral adiposity and colorectal adenoma in 1,205 eligible subjects. Odds ratios and 95% confidence intervals for colorectal adenoma were estimated by using an unconditional logistic regression model after adjustment for potential confounders. Despite its high correlation with body mass index, visceral fat volume was associated with the prevalence of colorectal adenoma independently of body mass index in both sexes. After further adjustment for body mass index, the odds ratio of colorectal adenoma for the highest compared with the lowest quartile of visceral fat volume was 1.58 (95% confidence interval: 1.11, 2.24) for men and women combined. Conversely, body mass index was unlikely to modify the association between visceral fat volume and colorectal adenoma ( $P_{\text{interaction}} = 0.39$ ). These findings add to accumulating evidence that visceral adiposity exerts an important influence on the pathogenesis of colorectal neoplasms. The mechanisms of this potential association between visceral adiposity and colorectal carcinogenesis warrant further investigation.

adenoma; case-control studies; intestine, large; intra-abdominal fat; Japan

Abbreviation: CI, confidence interval.

Obesity is associated with a large number of chronic diseases, including diabetes mellitus, hypertension, cardiovascular disease, and even some types of cancer (1). Of importance, a growing body of evidence suggests that the health risks of obesity relate to not only the amount of total body fat but also the distribution of body fat in the visceral region (1, 2). Visceral adiposity is a major determinant of insulin resistance, which has been suggested to be an early and fundamental disorder in the path to these obesity-related diseases (2).

In the last decade, a number of epidemiologic studies have reported an increase in the risk of colorectal adenoma (3–6) and cancer (3, 7–10) associated with a higher waist/hip ratio or waist circumference. Although these anthropometric measurements serve as surrogate markers of visceral adiposity, they mainly reflect the distribution of body fat in

the abdominal region without distinction between visceral and subcutaneous fat (11). In fact, although direct quantification of visceral fat requires imaging techniques, such as computed tomography and magnetic resonance imaging (11), we are aware of only 3 epidemiologic investigations of colorectal neoplasms that have used imaging techniques (12–14). Moreover, visceral adiposity in these studies was evaluated by the visceral fat area from a single abdominal cross-section only, and no previous study has measured the visceral fat volume of the abdominal cavity, which is the most comprehensive assessment of visceral adiposity.

Colorectal adenoma is recognized as a precursor lesion to the majority of colorectal cancers, and its presence is associated with an increased risk of colorectal cancer (15). Here, we quantified the visceral fat area and volume among middle-aged and elderly Japanese men and women using

**Table 1.** Selected Characteristics of Cases and Controls by Sex, the Colorectal Adenoma Study in Tokyo, Japan, 2004–2005

Characteristic	Men				<i>P</i> <sub>difference</sub> <sup>a</sup>	Women				<i>P</i> <sub>difference</sub> <sup>a</sup>
	Cases ( <i>N</i> = 432)		Controls ( <i>N</i> = 373)			Cases ( <i>N</i> = 205)		Controls ( <i>N</i> = 195)		
	No.	% <sup>b</sup>	No.	% <sup>b</sup>		No.	% <sup>b</sup>	No.	% <sup>b</sup>	
Age category, years					0.18					0.98
40–49						13	6	13	7	
50–54	61	14	69	19		23	11	25	13	
55–59	116	27	108	29		53	26	50	26	
60–64	114	26	95	25		68	33	61	31	
≥65	141	33	101	27		48	23	46	24	
Smoking status					<0.001					0.10
Never smoker	122	28	127	34		162	79	169	87	
Past smoker	202	47	200	54		28	14	19	10	
Current smoker	108	25	46	12		15	7	7	4	
Drinking status					0.19					0.16
Never drinker	45	10	50	13		98	48	96	49	
Past drinker	22	5	26	7		10	5	3	2	
Current drinker	365	84	297	80		97	47	96	49	
Family history of colorectal cancer					0.93					0.001
Yes	57	13	50	13		46	22	21	11	
No	375	87	323	87		159	78	174	89	
NSAID use					0.009					0.59
Yes	18	4	32	9		12	6	14	7	
No	414	96	341	91		193	94	181	93	
	Median	Interquartile Range	Median	Interquartile Range		Median	Interquartile Range	Median	Interquartile Range	
Total energy intake, kcal/day	1,931	1,601–2,350	1,945	1,570–2,279	0.75	1,826	1,465–2,159	1,778	1,369–2,078	0.12
Physical activity, MET-hours/day	33.8	30.9–38.5	33.7	31.6–37.7	0.51	35.5	31.8–42.5	36.1	31.3–42.0	0.98
Height, cm	167	163–171	167	163–171	0.65	155	151–158	154	151–158	0.31
Body mass index, kg/m <sup>2</sup>	24.0	22.4–25.7	23.5	21.7–25.1	0.008	22.5	20.6–24.2	21.8	20.3–23.6	0.09
Visceral fat area, cm <sup>2</sup>	99.5	75.9–130	92.6	67.1–119	0.005	70.9	51.5–91.3	68.2	49.2–88.2	0.25
Visceral fat volume, cm <sup>3</sup>	3,632	2,698–4,756	3,274	2,296–4,145	<0.001	2,123	1,505–2,801	1,880	1,390–2,575	0.02

Abbreviations: MET, metabolic equivalent task; NSAID, nonsteroidal antiinflammatory drug.

<sup>a</sup> Based on the chi-square test for percentage difference and the Wilcoxon rank-sum test for median difference.

<sup>b</sup> Percentages may not add to 100% because of rounding.

multislice computed tomography, and we examined the association between visceral adiposity and the prevalence of colorectal adenoma.

## MATERIALS AND METHODS

### Study population

The Research Center for Cancer Prevention and Screening was established in 2004 as a branch of the National Cancer Center of Japan with the goal of developing and

evaluating preventive methods, screening modalities, and screening programs for various types of cancers. Among its efforts, the Research Center conducted the Colorectal Adenoma Study in Tokyo (16, 17), a case-control study specifically designed to investigate environmental and genetic factors related to the early stage of colorectal carcinogenesis among healthy volunteer examinees of a colorectal cancer screening. All examinees gave written, informed consent to allow their data and materials collected through the screening to be used for medical research. The study protocol was approved by the institutional review board of the National Cancer Center, Tokyo, Japan.

**Table 2.** Association of Body Mass Index, Visceral Fat Area, and Visceral Fat Volume With Colorectal Adenoma, the Colorectal Adenoma Study in Tokyo, Japan, 2004–2005

Measurement	Quartile									
	1					2				
	Range	No. of Cases	No. of Controls	Odds Ratio	95% Confidence Interval	Range	No. of Cases	No. of Controls	Odds Ratio	95% Confidence Interval
Body mass index										
Men, kg/m <sup>2</sup>	<21.7	77	93			21.7–<23.5	102	93		
Crude estimate <sup>a</sup>				1	Referent				1.33	0.88, 2.02
Adjusted estimate <sup>b</sup>				1	Referent				1.36	0.88, 2.09
Women, kg/m <sup>2</sup>	<20.3	40	47			20.3–<21.8	45	50		
Crude estimate <sup>a</sup>				1	Referent				1.07	0.60, 1.94
Adjusted estimate <sup>b</sup>				1	Referent				1.03	0.55, 1.93
Men and women combined		117	140				147	143		
Crude estimate <sup>a</sup>				1	Referent				1.24	0.89, 1.74
Adjusted estimate <sup>b,c</sup>				1	Referent				1.25	0.89, 1.77
Visceral fat area										
Men, cm <sup>2</sup>	<67.1	76	93			67.1–<92.6	113	93		
Crude estimate <sup>a</sup>				1	Referent				1.49	0.99, 2.24
Adjusted estimate <sup>b</sup>				1	Referent				1.41	0.92, 2.16
Women, cm <sup>2</sup>	<49.2	45	48			49.2–<68.2	53	49		
Crude estimate <sup>a</sup>				1	Referent				1.15	0.64, 2.04
Adjusted estimate <sup>b</sup>				1	Referent				1.28	0.68, 2.38
Men and women combined		121	141				166	142		
Crude estimate <sup>a</sup>				1	Referent				1.36	0.98, 1.91
Adjusted estimate <sup>b,c</sup>				1	Referent				1.30	0.92, 1.84
Visceral fat volume										
Men, cm <sup>3</sup>	<2,296	77	93			2,296–<3,274	101	93		
Crude estimate <sup>a</sup>				1	Referent				1.33	0.88, 2.01
Adjusted estimate <sup>b</sup>				1	Referent				1.29	0.84, 1.99
Women, cm <sup>3</sup>	<1,390	34	48			1,390–<1,880	53	49		
Crude estimate <sup>a</sup>				1	Referent				1.63	0.89, 3.02
Adjusted estimate <sup>b</sup>				1	Referent				1.86	0.96, 3.60
Men and women combined		111	141				154	142		
Crude estimate <sup>a</sup>				1	Referent				1.41	0.99, 1.98
Adjusted estimate <sup>b,c</sup>				1	Referent				1.39	0.98, 1.97

Table continues

Eligible subjects were defined in advance as men aged 50–79 years and women aged 40–79 years who underwent total colonoscopy from the anus to the cecum and who were without a history of colorectal adenoma, any malignant neoplasm, ulcerative colitis, Crohn's disease, familial adenomatous polyposis, carcinoid tumor, or colectomy. Of a consecutive series of 3,212 examinees undergoing magnifying colonoscopy with indigo carmine dye spraying between February 2004 and February 2005, 2,234 met these conditions. On the basis of the pit pattern of colorectal lesions, namely, the characteristics of mucosal crypts, 526

men and 256 women were determined to have at least 1 adenomatous polyp and were thus included as adenoma cases. Pit-pattern classification based on magnifying chromoendoscopy has been detailed elsewhere (18). Of the remaining 1,452 examinees, 482 men and 721 women were identified as potential controls who were also free from other benign lesions (e.g., hyperplastic polyps, inflammatory polyps, and diverticula). For efficiency, 256 of the potential female controls were frequency matched to the female cases in 5 age categories (40–49, 50–54, 55–59, 60–64, and ≥65 years of age) and 2 screening periods (first

Table 2. Continued

Range	Quartile				Range	Quartile				<i>P</i> <sub>trend</sub>
	3					4				
	No. of Cases	No. of Controls	Odds Ratio	95% Confidence Interval		No. of Cases	No. of Controls	Odds Ratio	95% Confidence Interval	
23.5–<25.1	102	93	1.37	0.90, 2.07	≥25.1	151	94	1.98	1.33, 2.95	0.001
			1.40	0.91, 2.15				1.99	1.31, 3.03	0.001
21.8–<23.6	53	49	1.28	0.71, 2.30	≥23.6	67	49	1.64	0.92, 2.92	0.07
			1.47	0.78, 2.79				1.79	0.97, 3.31	0.03
	155	142				218	143			
			1.34	0.96, 1.88				1.85	1.33, 2.57	<0.001
			1.36	0.96, 1.93				1.88	1.34, 2.63	<0.001
92.6–<119	103	93	1.40	0.92, 2.12	≥119	140	94	1.80	1.20, 2.69	0.01
			1.29	0.84, 1.99				1.61	1.06, 2.46	0.05
68.2–<88.2	49	49	1.07	0.58, 1.95	≥88.2	58	49	1.26	0.70, 2.29	0.50
			1.17	0.61, 2.24				1.36	0.72, 2.58	0.42
	152	142				198	143			
			1.25	0.89, 1.76				1.58	1.14, 2.21	0.01
			1.18	0.83, 1.67				1.46	1.03, 2.06	0.06
3,274–<4,145	89	93	1.18	0.77, 1.80	≥4,145	165	94	2.13	1.43, 3.16	<0.001
			1.14	0.74, 1.76				2.02	1.33, 3.05	0.001
1,880–<2,575	47	49	1.45	0.77, 2.72	≥2,575	71	49	2.21	1.19, 4.08	0.02
			1.66	0.84, 3.30				2.55	1.31, 4.95	0.01
	136	142				236	143			
			1.24	0.87, 1.76				2.11	1.51, 2.94	<0.001
			1.21	0.85, 1.73				2.03	1.44, 2.86	<0.001

<sup>a</sup> Controlled for matching variables only.

<sup>b</sup> Additionally adjusted for cigarette smoking, alcohol drinking, physical activity, height, total energy intake, family history of colorectal cancer, and nonsteroidal antiinflammatory drug use.

<sup>c</sup> Further adjusted for sex.

and second halves). Because there were fewer potential male controls than male cases, all potential male controls were included in the study. Finally, the study enrolled 782 cases and 738 controls. Cases with adenomatous polyps of ≥5 mm in diameter were referred to clinical hospitals, including the National Cancer Center, for definitive diagnosis and treatment.

#### Visceral fat and anthropometric measurements

Among the study subjects, 1,214 (640 cases, 574 controls) underwent positron emission tomography/computed tomography as an additional cancer screening. Subjects were scanned in the supine position with a 16-detector row computed tomography scanner (Toshiba Medical

**Table 3.** Association of Visceral Fat Area and Visceral Fat Volume With Colorectal Adenoma After Adjustment for Body Mass Index, the Colorectal Adenoma Study in Tokyo, Japan, 2004–2005

Residual	Quartile												$P_{\text{trend}}$			
	1			2			3			4						
	No. of Cases	No. of Controls	Odds Ratio	95% Confidence Interval	No. of Cases	No. of Controls	Odds Ratio	95% Confidence Interval	No. of Cases	No. of Controls	Odds Ratio	95% Confidence Interval	No. of Cases	No. of Controls	Odds Ratio	95% Confidence Interval
<b>Residuals of visceral fat area<sup>a</sup></b>																
Men	114	93	1	Referent	85	93	0.68	0.45, 1.04	98	93	0.82	0.54, 1.26	135	94	0.98	0.65, 1.49
Adjusted estimate <sup>b</sup>																
Women	43	48	1	Referent	66	49	1.28	0.70, 2.33	43	49	0.93	0.49, 1.76	53	49	1.05	0.56, 1.97
Adjusted estimate <sup>b</sup>																
Men and women combined	157	141	1	Referent	151	142	0.90	0.64, 1.25	141	142	0.84	0.60, 1.18	188	143	0.99	0.71, 1.40
Adjusted estimate <sup>b,c</sup>																
<b>Residuals of visceral fat volume<sup>a</sup></b>																
Men	87	93	1	Referent	91	93	1.07	0.70, 1.63	110	93	1.29	0.84, 1.97	144	94	1.59	1.04, 2.45
Adjusted estimate <sup>b</sup>																
Women	35	48	1	Referent	55	49	1.56	0.83, 2.93	51	49	1.45	0.77, 2.74	64	49	1.90	1.00, 3.61
Adjusted estimate <sup>b</sup>																
Men and women combined	122	141	1	Referent	146	142	1.20	0.85, 1.69	161	142	1.28	0.90, 1.80	208	143	1.58	1.11, 2.24
Adjusted estimate <sup>b,c</sup>																

<sup>a</sup> Residuals of visceral fat area and visceral fat volume were derived from Willett's residual method (Willett WC. *Nutritional Epidemiology*, 2nd ed. New York, NY: Oxford University Press; 1998) (22) and were uncorrelated with body mass index.

<sup>b</sup> Adjusted for cigarette smoking, alcohol drinking, physical activity, height, total energy intake, family history of colorectal cancer, and nonsteroidal antiinflammatory drug use, as well as matching variables.

<sup>c</sup> Further adjusted for sex.

Systems, Tochigi, Japan) and the following scan conditions: 120 kV, scanning time of 0.5 second/rotation, and computed tomography automatic exposure control with a standard deviation of 20. The scanner computer reconstructed the raw data to give cross-sectional images with a 5-mm slice thickness by using a function for abdominal kernel.

The visceral fat area and volume were quantified by using specifically designed software (Fujifilm Medical, Tokyo, Japan), with the case and control status unknown. A function of the software enables the automatic drawing of a contour line around the abdominal cavity, which helps to separate the subcutaneous and intraabdominal regions. Details of the software have been described elsewhere (19). To measure visceral fat volume, we first selected a series of reconstruction images from immediately below the diaphragmatic surface of the heart to the cranial edge of the pubic symphysis, minimizing the influence of pericardial and mediastinal adipose tissue. The visceral fat area was then computed in each image by electronically determining pixels with attenuation values between  $-190$  and  $-30$  Hounsfield units in the intra-abdominal region. Finally, the visceral fat volume was calculated by integrating these visceral fat areas of respective images with a 5-mm slice thickness.

Body weight and height were measured by medical personnel at the beginning of cancer screening. Body mass index was calculated ( $\text{weight (kg)}/\text{height (m)}^2$ ). The waist/hip ratio was not calculated because waist and hip circumferences were not measured during the study period.

#### Self-administered questionnaire

Prior to cancer screening, examinees completed a self-administered questionnaire that included items on personal medical history, present medication, family history of cancer, cigarette smoking, alcohol drinking, physical activity, and other lifestyle factors. The questionnaire has been described in detail elsewhere (16, 17).

The questionnaire also included a food frequency questionnaire of 145 food and beverage items with standard portions/units and 9 frequency categories. Total energy intake was estimated from the responses by reference to the *Standard Tables of Food Composition in Japan*, Fifth Revised Edition (20). The food frequency questionnaire of the present study was essentially the same as that used in a large prospective study among a Japanese population (21).

#### Statistical analysis

An unconditional logistic regression model was used to estimate odds ratios and their 95% confidence intervals of colorectal adenoma according to sex-specific quartiles of body mass index, visceral fat area, and visceral fat volume, with the lowest quartile for each measurement used as the reference. The first analysis controlled for matching variables (i.e., age categories and screening periods), while the second additionally adjusted for the following covariates: cigarette smoking (never,  $\leq 20$ , 21–40,  $> 40$  pack-years), alcohol drinking (never, past,  $< 150$ , 150–299,  $\geq 300$  g per week), family history of colorectal cancer (yes or no), and nonsteroidal antiinflammatory drug use (yes or no). These

covariates were suggested to be potential confounders in previous reports from the Colorectal Adenoma Study in Tokyo (16, 17). The second analysis also adjusted for components or surrogate indicators of energy balance, namely, total energy intake in kilocalories per day, physical activity in metabolic equivalent hours per day, and height in centimeters. These continuous variables were, respectively, divided into quartiles, the cutoff points of which were based on the sex-specific distribution among controls. Linear trends in the odds ratios of colorectal adenoma were also assessed by assigning ordinal values to quartiles of each measurement. Finally, we combined men and women according to sex-specific quartiles of body mass index, visceral fat area, and visceral fat volume, respectively, and examined whether the association of each measurement was modified by sex. An interaction term was created by multiplying ordinal values for quartiles of each measurement by those for dichotomous categories of sex, and its significance was statistically evaluated by the likelihood ratio test with 1 df.

In a preliminary analysis, the visceral fat area and visceral fat volume were found to be highly correlated with body mass index in both sexes, with Pearson's correlation coefficients of 0.66 and 0.74, respectively, for male controls and 0.66 and 0.72, respectively, for female controls (all  $P$  values  $< 0.001$ ). These strong correlations notwithstanding, we were interested to know whether the visceral fat area and visceral fat volume were associated with colorectal adenoma independently of body mass index. To investigate this, we applied Willett's residual method for energy adjustment of food intake (22) and calculated residuals of the visceral fat area and visceral fat volume using linear regression models with body mass index as the independent variable. These residuals were uncorrelated with body mass index, which enabled us to evaluate the association of visceral fat area and visceral fat volume with colorectal adenoma after adjustment for body mass index.

Of 1,214 subjects who underwent both colonoscopy and positron emission tomography/computed tomography, 9 had missing information, namely, 3 with regard to body mass index, 2 for tobacco smoking, and 4 for physical activity. These were then excluded, and the current analysis was conducted in 805 men (432 cases, 373 controls) and 400 women (205 cases, 195 controls). Two-sided  $P$  values of less than 0.05 were regarded as statistically significant. All statistical analyses were carried out by using Statistical Analysis System (SAS), Version 9.1, software (SAS Institute, Inc., Cary, North Carolina).

#### RESULTS

The visceral fat volume was evaluated from immediately below the diaphragmatic surface of the heart to the cranial edge of the pubic symphysis, while the visceral fat area was examined at the level of the umbilicus. Table 1 shows that the degree of visceral adiposity differed considerably between men and women, with the median visceral fat volume approximately 74% greater in male than female controls. Table 1 also summarizes selected characteristics of cases and controls

**Table 4.** Association of Visceral Fat Area and Visceral Fat Volume With Colorectal Adenoma Stratified by Body Mass Index, the Colorectal Adenoma Study in Tokyo, Japan, 2004–2005

Measurement	Quartile									
	1					2				
	Range	No. of Cases	No. of Controls	Odds Ratio	95% Confidence Interval	Range	No. of Cases	No. of Controls	Odds Ratio	95% Confidence Interval
Visceral fat area <sup>a</sup>										
Men, cm <sup>2</sup>	<67.1					67.1–<92.6				
Women, cm <sup>2</sup>	<49.2					49.2–<68.2				
Lower body mass index <sup>c</sup>		107	125				88	82		
Adjusted estimate <sup>d</sup>				1	Referent				1.16	0.77, 1.76
Higher body mass index <sup>c</sup>		14	16				78	60		
Adjusted estimate <sup>d</sup>				1.15	0.52, 2.55				1.55	0.99, 2.41
Visceral fat volume <sup>a</sup>										
Men, cm <sup>3</sup>	<2,296					2,296–<3,274				
Women, cm <sup>3</sup>	<1,390					1,390–<1,880				
Lower body mass index <sup>c</sup>		102	126				92	87		
Adjusted estimate <sup>d</sup>				1	Referent				1.28	0.85, 1.92
Higher body mass index <sup>c</sup>		9	15				62	55		
Adjusted estimate <sup>d</sup>				0.72	0.29, 1.78				1.45	0.91, 2.31

Table continues

by sex. Current smokers were more prevalent among male cases than controls, whereas nonsteroidal antiinflammatory drug use was more common among male controls than cases. On the other hand, a family history of colorectal cancer was more frequent among female cases than controls.

Table 2 shows the odds ratios of colorectal adenoma according to sex-specific quartiles of body mass index, visceral fat area, and visceral fat volume. We observed a statistically significant trend of increasing adjusted odds ratios for colorectal adenoma across quartiles of body mass index in both men and women ( $P_{\text{trend}} = 0.001$  and  $0.03$ , respectively). A statistically significant odds ratio was also seen among men in the highest quartile. Adjusted odds ratios of colorectal adenoma for the highest compared with the lowest quartile of body mass index were 1.99 (95% confidence interval (CI): 1.31, 3.03) for men and 1.79 (95% CI: 0.97, 3.31) for women. Of the 2 measurements of visceral adiposity, an increase in visceral fat volume was related to a higher prevalence of colorectal adenoma, with a significant trend in both sexes ( $P_{\text{trend}} = 0.001$  and  $0.01$  for men and women, respectively), whereas the visceral fat area was not associated with colorectal adenoma in either sex ( $P_{\text{trend}} = 0.05$  and  $0.42$  for men and women, respectively). Adjusted odds ratios of colorectal adenoma for the highest compared with the lowest quartile of visceral fat area and visceral fat volume were 1.61 (95% CI: 1.06, 2.46) and 2.02 (95% CI: 1.33, 3.05), respectively, for men and 1.36 (95% CI: 0.72, 2.58) and 2.55 (95% CI: 1.31, 4.95), respectively, for women. When men and women were combined according to sex-specific quartiles of each mea-

surement, a significant trend of increasing adjusted odds ratios across quartiles became more pronounced for body mass index and visceral fat volume ( $P_{\text{trend}} < 0.001$  for both), while the nonsignificant trend for visceral fat area remained ( $P_{\text{trend}} = 0.06$ ). Despite the sex differences in body mass and visceral adiposity, significant effect modification by sex was not observed for any of 3 measurements ( $P_{\text{interaction}} = 0.75$ ,  $0.30$ , and  $0.87$  for body mass index, visceral fat area, and visceral fat volume, respectively; data not shown).

To investigate the influence of visceral fat area and visceral fat volume after adjustment for body mass index, we calculated residuals of visceral fat area and visceral fat volume against body mass index, which were uncorrelated with body mass index. As shown in Table 3, no material association was seen between visceral fat area and colorectal adenoma after adjustment for body mass index. In contrast, visceral fat volume was related to a higher prevalence of colorectal adenoma even after adjustment for body mass index. Adjusted odds ratios of colorectal adenoma for the highest compared with the lowest quartile of residuals of visceral fat area and visceral fat volume were 0.99 (95% CI: 0.71, 1.40) and 1.58 (95% CI: 1.11, 2.24), respectively, for men and women combined. Further, a positive trend across quartiles was statistically significant ( $P_{\text{trend}} = 0.01$ ) for visceral fat volume. Again, significant effect modification by sex was not observed for either measurement of visceral adiposity ( $P_{\text{interaction}} = 0.53$  and  $0.83$  for visceral fat area and visceral fat volume, respectively; data not shown). These residual analyses revealed that visceral fat volume